Roche’s Kadcyla gets EC nod as adjuvant treatment for HER2-positive early breast cancer

This article was originally published here

Kadcyla will be used to treat the patients who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy. Kadcyla

The post Roche’s Kadcyla gets EC nod as adjuvant treatment for HER2-positive early breast cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply